Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01290341 · ClinicalTrials.gov registry record · Phase 3
Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis
A Phase 3 study, sponsored by Merz North America.
- Completed
- Registry status
- Phase 3
- Development phase
- 860
- Enrollment target
NCT01290341 is a Phase 3 study that has completed, run by Merz North America. The registered enrollment target is 860 participants.
The verdict
NCT01290341, a Phase 3 study, has completed, sponsored by Merz North America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 860 participants
- Enrollment target
Study Summary
This is a 6-week, double-blind, randomized, placebo-controlled, multicenter, parallel group Phase 3 study of NAFT-600 applied once a day for 2 weeks compared to vehicle (placebo) in the treatment of tinea pedis.
Interventions
- DRUG Placebo
- DRUG NAFT-600 (naftin 2 % gel)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 860 participants |
| Start Date | 2011-02 |
| Est. Completion | 2011-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01290341
The ClinicalTrials.gov registry entry for NCT01290341 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 860 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merz North America, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01290341 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01290341 about?
NCT01290341 is a clinical study titled "Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis". This is a 6-week, double-blind, randomized, placebo-controlled, multicenter, parallel group Phase 3 study of NAFT-600 applied once a day for 2 weeks compared to vehicle (placebo) in the treatment of tinea pedis.
What is the current status of trial NCT01290341?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 860 participants. The study started on 2011-02. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01290341?
The interventions under investigation include: Placebo (DRUG), NAFT-600 (naftin 2 % gel) (DRUG).
Who is sponsoring clinical trial NCT01290341?
This trial is sponsored by Merz North America, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.